Chronic Cough

In November, all but one of the members of the FDA’s Pulmonary-Allergy Drugs Advisory Committee voted against recommending the approval of gefapixant for adults with refractory or unexplained chronic cough.

In a 12-to-1 vote, the FDA’s Pulmonary-Allergy Drug Advisory Committee voted against approving gefapixant 45 mg tablets to treat adults with refractory or unexplained chronic cough.

Gefapixant only showed small effects vs. placebo on objective cough frequency, cough severity and quality of life among adults with refractory or unexplained chronic cough, according to results of a systematic review and meta-analysis.

PARK CITY, Utah — Chronic cough has a variety of causes in children, with broad options for treatment, according to a talk at the Association of PAs in Allergy, Asthma and Immunology Annual Allergy, Asthma & Immunology CME Conference.

PARK CITY, Utah — The state of care in eosinophilic esophagitis and chronic cough were among the topics at the Association of PAs in Allergy, Asthma and Immunology Annual Allergy, Asthma & Immunology Conference.

SAN ANTONIO — Almost one-quarter of patients with chronic cough evaluated in the primary care setting saw their symptoms unresolved 18 months later, according to data presented here.

The FDA granted orphan drug designation to ifenprodil for the treatment of patients with idiopathic pulmonary fibrosis, according to a press release from the drug’s manufacturer.

Current treatments for chronic cough fail to effectively resolve its symptoms, indicating a need to develop new therapies, according to the results of a survey of allergy specialists published in Annals of Allergy, Asthma & Immunology.

In China, chronic cough is prevalent and associated with poorer health status, especially among adults aged at least 50 years and those with COPD or small airway dysfunction, researchers reported.